Literature DB >> 17284347

Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease.

I Ferrer1, E Perez, E Dalfó, M Barrachina.   

Abstract

Prohibitin and ATP synthase protein levels were examined in the substantia nigra and frontal cortex (area 8) in five cases of Parkinson's disease (PD), five cases of dementia with Lewy bodies pure form (pDLB), five cases of early Alzheimer's disease (AD stage IIA, B), nine cases with advanced AD (stages V/VIC), and nine controls. A significant reduction of prohibitin and ATP synthase was observed in the substantia nigra in PD cases. In contrast, increased prohibitin and ATP synthase levels were found in the frontal cortex in PD, and increased prohibitin but not ATP synthase in the frontal cortex in pDLB. Superoxide dismutase 2 (SOD2) expression levels were also increased in the frontal cortex in PD and pDLB. No modifications in prohibitin and ATP synthase levels were found in the frontal cortex in sporadic AD. These findings demonstrate disease-specific modifications in the expression of mitochondrial-related proteins in the frontal cortex at stages of PD in which there is no alpha-synuclein aggregation in the form of Lewy bodies and Lewy neurites in this area. These findings emphasize the presence of mitochondrial modifications before the appearance of histological hallmarks of PD, and point to the possibility of a more extended molecular pathology in PD than currently accepted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17284347     DOI: 10.1016/j.neulet.2007.01.026

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  24 in total

1.  Cypermethrin-induced nigrostriatal dopaminergic neurodegeneration alters the mitochondrial function: a proteomics study.

Authors:  Sonal Agrawal; Ashish Singh; Pratibha Tripathi; Manisha Mishra; Pradhyumna Kumar Singh; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2014-04-24       Impact factor: 5.590

2.  Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.

Authors:  Debashis Dutta; Nilufar Ali; Emili Banerjee; Raghavendra Singh; Amit Naskar; Ramesh Kumar Paidi; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

Review 3.  Control of mitochondrial integrity in ageing and disease.

Authors:  Radek Szklarczyk; Marco Nooteboom; Heinz D Osiewacz
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-07-05       Impact factor: 6.237

4.  Prohibitin reduces mitochondrial free radical production and protects brain cells from different injury modalities.

Authors:  Ping Zhou; Liping Qian; Marilena D'Aurelio; Sunghee Cho; Gang Wang; Giovanni Manfredi; Virginia Pickel; Costantino Iadecola
Journal:  J Neurosci       Date:  2012-01-11       Impact factor: 6.167

5.  Prohibitin protects against oxidative stress-induced cell injury in cultured neonatal cardiomyocyte.

Authors:  Xiaohua Liu; Zhe Ren; Rui Zhan; Xinxing Wang; Xiaoming Wang; Zhiqing Zhang; Xue Leng; Zhihua Yang; Lingjia Qian
Journal:  Cell Stress Chaperones       Date:  2008-10-29       Impact factor: 3.667

Review 6.  Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.

Authors:  S L Sison; S C Vermilyea; M E Emborg; A D Ebert
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-04       Impact factor: 5.081

Review 7.  Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.

Authors:  Britney N Lizama; Amy M Palubinsky; BethAnn McLaughlin
Journal:  Neurochem Int       Date:  2017-08-26       Impact factor: 3.921

8.  Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.

Authors:  Katrin Beyer; Montserrat Domingo-Sàbat; Jordi Humbert; Cristina Carrato; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2008-03-12       Impact factor: 2.660

Review 9.  SOD2 in mitochondrial dysfunction and neurodegeneration.

Authors:  James M Flynn; Simon Melov
Journal:  Free Radic Biol Med       Date:  2013-05-29       Impact factor: 7.376

Review 10.  Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins.

Authors:  D Allan Butterfield; Erika M Palmieri; Alessandra Castegna
Journal:  Expert Rev Proteomics       Date:  2016       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.